1. GPCR/G Protein
    Neuronal Signaling
    Metabolic Enzyme/Protease
  2. Dopamine Receptor
    Endogenous Metabolite
  3. L-DOPA

L-DOPA (Synonyms: Levodopa; 3,4-Dihydroxyphenylalanine)

Cat. No.: HY-N0304 Purity: 99.97%
Handling Instructions

L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease.

For research use only. We do not sell to patients.

L-DOPA Chemical Structure

L-DOPA Chemical Structure

CAS No. : 59-92-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
200 mg USD 60 In-stock
Estimated Time of Arrival: December 31
1 g USD 84 In-stock
Estimated Time of Arrival: December 31
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease. L-DOPA is the precursor of dopamine and product of tyrosine hydroxylase. Target: Dopamine Receptor L-DOPA (L-3,4-dihydroxyphenylalanine) is a chemical that is made and used as part of the normal biology of humans, some animals and plants. Some animals and humans make it via biosynthesis from the amino acid L-tyrosine. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine collectively known as catecholamines. L-DOPA can be manufactured and in its pure form is sold as apsychoactive drug with the INN levodopa; trade names include Sinemet, Parcopa, Atamet, Stalevo, Madopar, Prolopa, etc. As a drug it is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia. L-DOPA crosses the protective blood-brain barrier, whereas dopamine itself cannot. Thus, L-DOPA is used to increase dopamine concentrations in the treatment of Parkinson's disease and dopamine-responsive dystonia. This treatment was made practical and proven clinically by George Cotzias and his coworkers, for which they won the 1969 Lasker Prize. In addition, L-DOPA, co-administered with a peripheral DDCI, has been investigated as a potential treatment for restless leg syndrome. However, studieshave demonstrated "no clear picture of reduced symptoms".

IC50 & Target

Human Endogenous Metabolite


Clinical Trial
Molecular Weight







N[[email protected]@H](CC1=CC(O)=C(C=C1)O)C(O)=O


Room temperature in continental US; may vary elsewhere.


4°C, stored under nitrogen

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

H2O : 2 mg/mL (10.14 mM; Need ultrasonic and warming)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.0713 mL 25.3563 mL 50.7125 mL
5 mM 1.0143 mL 5.0713 mL 10.1425 mL
10 mM 0.5071 mL 2.5356 mL 5.0713 mL
*Please refer to the solubility information to select the appropriate solvent.
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


L-DOPALevodopa3,4-DihydroxyphenylalanineDopamine ReceptorEndogenous MetaboliteInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product name:
Cat. No.:
MCE Japan Authorized Agent: